PCI Biotech Holding ASA (OSL:PCIB)

Norway flag Norway · Delayed Price · Currency is NOK
0.2810
-0.0220 (-7.26%)
Oct 3, 2025, 4:17 PM CET
-7.26%
Market Cap11.31M
Revenue (ttm)4.69M
Net Income (ttm)-20.54M
Shares Out37.33M
EPS (ttm)-0.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume212,825
Average Volume301,119
Open0.3000
Previous Close0.3030
Day's Range0.2670 - 0.3440
52-Week Range0.2610 - 2.2200
Beta1.73
RSI24.50
Earnings DateNov 18, 2025

About PCI Biotech Holding ASA

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development of technologies and novel therapies through its photochemical technology platform. The company’s technology platform consists of a proprietary small molecule photosensitiser and a light source; and develops photochemical lysis (PCL) comprising light-triggered cell lysis, which enhances yield and purity in viral vector manufacturing, as well as photochemical internalisation (PCI), inducing light-triggered intracellular release for various therapeutic modalities. It ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 5
Stock Exchange Oslo Børs
Ticker Symbol PCIB
Full Company Profile

Financial Performance

In 2024, PCI Biotech Holding ASA's revenue was 6.74 million, an increase of 125.25% compared to the previous year's 2.99 million. Losses were -16.42 million, -19.19% less than in 2023.

Financial Statements

News

There is no news available yet.